Detailed Program Corporate Sessions

Monday, 17 June 2019  | 12:45 – 14:15

Hall 513 ABC

12:45 – 14:15

Addressing unmet needs in Parkinson’s disease
– supported by an unrestricted grant from Sunovion Pharmaceuticals Inc.

Welcome, Introductions and Rules of the “Game”
Tanya Simuni (USA)

Opportunity 1: Making the case for continued investment in agents for motor and non-motor fluctuations in Parkinson’s disease
Hubert Fernandez (USA)

Opportunity 2: Making the case for investing in agents that address dementia in Parkinson’s disease
Irene Litvan (USA)

Opportunity 3: Making the case for investing in agents that address psychosis in Parkinson’s disease
Daniel Weintraub (USA)

 

Hall 513 DEF

12:45 – 14:15

Tomorrow does not have to be disrupted – The First and Only Medication Clinically Proven to Reduce Dyskinesia and OFF Time in Patients with Parkinson’s Disease
– supported by an unrestricted grant from Adamas Pharmaceuticals, Inc

Chair:Robert Hauser (USA)
Chair: Mark Lew (USA)
Chair: Rajesh Pahwa (USA)

Learning Objectives:

  • Discuss the burden of dyskinesia and motor fluctuations in Parkinson’s disease and unmet needs with dopaminergic therapy
  • Consider the role of glutamate in motor fluctuations
  • Explore an adjunctive therapeutic option to modulate the glutamate pathway
Tuesday, 18 June 2019 | 12:45 – 14:15

Hall 513 ABC

12:45 – 14:15

Motor fluctuations in Parkinson’s disease: What are we missing?
– supported by an unrestricted grant from Neurocrine

Chair: Mark Lew (USA)
Chair: Daniel Claasen (USA)

Learning Objectives:

  • Discuss the mechanisms of motor fluctuations in PD
  • Describe the spectrum of ON/OFF and how motor fluctuations lead to clinical features impacting function and quality of life for patients and caregivers
  • Review current methods in identification and management of motor fluctuations